The Problem with Conventional Sexual Health Treatments
Most sexual health medications address the vascular or hormonal mechanics of sex — improving blood flow (PDE5 inhibitors) or supplementing declining hormones (TRT, estrogen therapy). These work for physical dysfunction but miss the most common complaint: low desire or motivation.
PT-141 is different. It activates melanocortin receptors in the brain — specifically in pathways governing sexual motivation and reward — which directly increases desire. It's the only sexual health medication with this central mechanism of action, which is why it works for patients whose primary issue is libido rather than physical performance.
For Women
- →FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women
- →Used off-label for post-menopausal sexual dysfunction
- →Addresses desire and arousal, not just physical response
- →Can be used alongside hormone therapy
For Men
- →Off-label for libido-driven erectile dysfunction
- →Adjunct to TRT when desire remains low despite optimized testosterone
- →Situational performance issues with psychological component
- →Works when PDE5 inhibitors don't address the root issue
How PT-141 Compares
| Treatment | Mechanism | Works for women? | Addresses desire? |
|---|---|---|---|
| PT-141 | Brain melanocortin receptors | Yes (FDA approved) | Yes — primary effect |
| Viagra / Cialis | PDE5 inhibitor (vascular) | No approved use | No |
| TRT | Testosterone replacement | Limited / off-label | Indirectly |
| Estrogen therapy | Hormone replacement | Yes | Indirectly |
Learn more: Full PT-141 guide →